Project Name: Multiple Sclerosis (MS) Capacity redesign

Project Summary:

The collaborative working project (CWP) is a proof of concept with the aim to redesign the CW Partner’s multiple sclerosis (MS) service with the addition of an MS disease modifying therapy (DMT) coordinator based at Huddersfield Royal Infirmary. The MS DMT Coordinator will support the management, monitoring and onward referral of MS patients on DMTs. This will address the capacity issues being experienced by the CW Partner, help to tackle the backlog of patients, and address the risk of delays in starting and switching treatments.

Planned Milestones:

  • CW Partner & Novartis. Project kick off meeting and set up of subsequent quarterly reviews
  • CW Partner. Recruitment of MS DMT coordinator and baseline measurements submitted. Define roles and responsibilities of MS DMT coordinator.
  • CW Partner. 3-month data collection. CW Partner & Novartis. Project review meeting.
  • CW Partner. 6 month data collection. CW Partner & Novartis. Project review meeting
  • CW Partner. 9 month data Collection. CW Partner & Novartis. Project review meeting.
  • CW Partner. 12 month data collection. CW Partner & Novartis. Project review meeting.
  • CW Partner. Business case written & submitted.
  • CW Partner. Project Outcomes Summary completed.
  • CW Partner & Novartis. Project wrap up meeting.

Expected Benefits:

Anticipated benefits for patients:

  • Improved patient outcomes due to faster time from referral to treatment time.
  • Improved access to appropriate recommended therapies.
  • Enhanced patient experience of the NHS MS service by reducing unnecessary waiting times.

Anticipated benefits for the organisations:

  • Improved quality of care.
  • Reduction in patient waiting lists.
  • Improved MDT efficiency and outcomes.
  • Improved experience of staff by spreading workload.

Anticipated benefits for Novartis:

  • Learnings relating to the involvement of MS DMT coordinator at MDTs.
  • Better understanding of overall customers’ and patients’ needs.
  • Optimal use of medicines (including Novartis medicines) in appropriate patients.

Start Date & Duration: December 2024, unless terminated early in accordance with its terms shall subsist until completion of the Project or September 2026, whichever first occurs.

FA-11334668 | January 2025